STORZ SURGICAL OPHTHALMIC PACK STERILITY PROBLEMS
This article was originally published in The Gray Sheet
Executive SummarySTORZ SURGICAL OPHTHALMIC PACK STERILITY PROBLEMS cited by FDA in a recent warning letter to the company. The agency lists 17 violations of good manufacturing practices regulations, most of them related to product sterility. The letter follows a March 14 through May 25 inspection of the company's St. Louis production plant.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.